Healthcare & Life Sciences
RheumaGen, Inc.
United States
aliveseries-a
series-a
Stage
About
RheumaGen, Inc. is developing HLA-targeted gene-editing therapies aimed at treating major autoimmune diseases, supported by a $15 million Series A financing round.
Explore RheumaGen, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.